{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:36:46Z","timestamp":1772271406913,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development","award":["15ck0106039h0002"],"award-info":[{"award-number":["15ck0106039h0002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2329-7","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T17:02:54Z","timestamp":1462294974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer"],"prefix":"10.1186","volume":"16","author":[{"given":"Satoshi","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madoka","family":"Morota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minako","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Igaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Itami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,3]]},"reference":[{"key":"2329_CR1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijrobp.2009.01.078","volume":"76","author":"NN Stone","year":"2010","unstructured":"Stone NN, Stock RG, Cesaretti JA, Unger P. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys. 2010;76:355\u201360.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2329_CR2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2004.10.014","volume":"74","author":"L \u00c5str\u00d6m","year":"2005","unstructured":"\u00c5str\u00d6m L, Pedersen D, Mercke C, Holm\u00e4ng S, Ohanssoon KA. Long-term outcome of high dose rate brachytherapy in radiotherapy of localized prostate cancer. Radiationther Oncol. 2005;74:157\u201361.","journal-title":"Radiationther Oncol"},{"key":"2329_CR3","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0022-5347(17)36967-7","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler Jr FJ, O\u2019Leray MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol. 1992;148:1558\u201363. discussion 1564.","journal-title":"J Urol"},{"key":"2329_CR4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00066-008-1833-3","volume":"184","author":"N Murakami","year":"2008","unstructured":"Murakami N, Itami J, Okuma K, Hiroshi M, Keiichi N, Tsukasa B, et al. Urethral doseand increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer. Strahlenther Onkol. 2008;184:515\u20139.","journal-title":"Strahlenther Onkol"},{"key":"2329_CR5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.radonc.2005.04.002","volume":"75","author":"A Mahmoudieh","year":"2005","unstructured":"Mahmoudieh A, Tremblay C, Beaulieu L, Lachance B, Harel F, Lessard E, et al. Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study. Radiother Oncol. 2005;75:318\u201324.","journal-title":"Radiother Oncol"},{"key":"2329_CR6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.radonc.2013.09.025","volume":"110","author":"P Hoskin","year":"2014","unstructured":"Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G, et al. High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity. Radiother Oncol. 2014;110:268\u201371.","journal-title":"Radiother Oncol"},{"key":"2329_CR7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brachy.2012.05.003","volume":"12","author":"R Kotecha","year":"2013","unstructured":"Kotecha R, Yamada Y, Pei X, Kollmeier MA, Cox B, Cohen GN, et al. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy. 2013;12:44\u20139.","journal-title":"Brachytherapy"},{"key":"2329_CR8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ijrobp.2011.06.2013","volume":"83","author":"K Forsythe","year":"2012","unstructured":"Forsythe K, Blacksburg S, Stone N, Stock RG. Intensity-Modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer. Int Radiat Oncol Biol Phys. 2012;83:630\u20135.","journal-title":"Int Radiat Oncol Biol Phys"},{"key":"2329_CR9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bju.12514","volume":"114","author":"DE Spratt","year":"2014","unstructured":"Spratt DE, Zumsteg ZS, Ghadjar P, Kollmeier MA, Pei X, Cohen G, et al. Comparison of high-dose (86.4\u00a0Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int. 2014;114:360\u20137.","journal-title":"BJU Int"},{"key":"2329_CR10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijrobp.2009.05.046","volume":"76","author":"J Hermesse","year":"2010","unstructured":"Hermesse J, Biver S, Jansen N, Lenaerts E, Nickers P. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate. Int J Radiat Oncol Biol Phys. 2010;76:269\u201376.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2329_CR11","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1002\/cncr.25537","volume":"116","author":"LH Sobin","year":"2010","unstructured":"Sobin LH, Compton CC. TNM seventh edition: what\u2019s new, what\u2019s changed: communication from the international Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116:5336\u20139.","journal-title":"Cancer"},{"key":"2329_CR12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00066-014-0675-4","volume":"190","author":"K Yoshida","year":"2014","unstructured":"Yoshida K, Yamazaki H, Takenaka T, Kotsuma T, Yoshida M, Masui K, et al. High-dose-rate interstitial brachytherapy in combination with androgen deprivation therapy for prostate cancer. Strahlenther Onkol. 2014;190:1015\u201320.","journal-title":"Strahlenther Onkol"},{"key":"2329_CR13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.brachy.2010.02.196","volume":"9","author":"I Deutsch","year":"2010","unstructured":"Deutsch I, Zelefsky MJ, Zhang Z, Mo Q, Zaider M, Cohen G, et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy. 2010;9:313\u20138.","journal-title":"Brachytherapy"},{"key":"2329_CR14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijrobp.2009.10.035","volume":"79","author":"AA Martinez","year":"2011","unstructured":"Martinez AA, Gonzalez J, Ye H, Ghilezan M, Shetty S, Kernen K, et al. Dose escalation improves cancer-related events at 10\u00a0years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79:363\u201370.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2329_CR15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0360-3016(99)00351-X","volume":"46","author":"S Nag","year":"2000","unstructured":"Nag S, Bice W, DeWyngaert K, Prestidge B, Stock R, Yu Y. The American brachytherapy recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 2000;46:221\u201330.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2329_CR16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00066-008-1886-3","volume":"184","author":"M Pinkawa","year":"2008","unstructured":"Pinkawa M, Gagel B, Asadpour B, Piroth MD, Klotz J, Borchers H, et al. Seed displacements after permanent brachytherapy for prostate cancer in dependence on the prostate level. Strahlenther Onkol. 2008;184:520\u20135.","journal-title":"Strahlenther Onkol"},{"key":"2329_CR17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2007.01.014","volume":"83","author":"C Salembier","year":"2007","unstructured":"Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A, et al. Tumor and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO\/EAU\/EORTC recommendations on prostate brachytherapy. Radiother Oncol. 2007;83:3\u201310.","journal-title":"Radiother Oncol"},{"key":"2329_CR18","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1118\/1.598418","volume":"25","author":"GM Daskalov","year":"1998","unstructured":"Daskalov GM, L\u00f6ffler E, Williamson JF. Monte Carlo-aided dosimetry of a new high dose-rate brachytherapy source. Med Phys. 1998;25:2200\u20138.","journal-title":"Med Phys"},{"key":"2329_CR19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1118\/1.3531973","volume":"38","author":"D Granero","year":"2011","unstructured":"Granero D, Vijande J, Ballester F, Rivard MJ. Dosimetry revisited for the HDR 192Ir brachytherapy source model mHDR-v2. Med Phys. 2011;38:487\u201394.","journal-title":"Med Phys"},{"key":"2329_CR20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1259\/0007-1285-58-690-515","volume":"58","author":"RG Dale","year":"1985","unstructured":"Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985;58:515\u201328.","journal-title":"Br J Radiol"},{"key":"2329_CR21","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00259-013-2383-1","volume":"40","author":"F Botta","year":"2013","unstructured":"Botta F, Cremonesi M, Ferrari ME, Amato E, Guerriero F, Vavassori A, et al. Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I-II clinical study. Eur J Nucl Med Mol Imaging. 2013;40:1047\u201356.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2329_CR22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijrobp.2013.10.042","volume":"88","author":"P Ghadjar","year":"2014","unstructured":"Ghadjar P, Zelefsky MJ, Spratt DE, Munck af Rosensch\u00f6ld P, Oh JH, Hunt M, et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2014;88:339\u201344.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2329_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OAJU.S15333","volume":"3","author":"MC Gittelman","year":"2010","unstructured":"Gittelman MC, Marks LS, Hill LA, Volinn W, Hoel G. Effect of silodosin on specific urinary symptoms associated with benign prostatic hyper plasia: analysis of international prostate symptom scores in 2 phase III clinical studies. Open Access J Urol. 2010;3:1\u20135.","journal-title":"Open Access J Urol"},{"key":"2329_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cncr.23139","volume":"112","author":"MC Abramowitz","year":"2008","unstructured":"Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2008;112:55\u201360.","journal-title":"Cancer"},{"key":"2329_CR25","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.juro.2015.05.077","volume":"194","author":"K Spradling","year":"2015","unstructured":"Spradling K, Khoyilar C, Abedj G, Okhunov Z, Wikenheiser J, Yoon R, et al. Redefining the Autonomic Nerve Distribution of the Bladder Using 3-Dimensional Image Reconstruction. J Urol. 2015;194:1661\u20137.","journal-title":"J Urol"},{"key":"2329_CR26","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.radonc.2014.10.007","volume":"113","author":"P D\u00edez","year":"2014","unstructured":"D\u00edez P, Mullassery V, Dankulchai P, Ostler P, Hughes R, Alonzi R, et al. Dosimetric analysis of urethral strictures following HDR (192)Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer. Radiother Oncol. 2014;113:410\u20133.","journal-title":"Radiother Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2329-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T05:28:14Z","timestamp":1718515694000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2329-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,3]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2329"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2329-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,3]]},"article-number":"296"}}